Welcome to our dedicated page for Pds Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on Pds Biotechnology Corporation stock.
PDS Biotechnology Corporation (NASDAQ: PDSB) delivers innovative immunotherapies through its Versamune® platform, targeting cancers and infectious diseases. This news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and corporate developments.
Access primary-source press releases and curated analysis covering PDSB's clinical trials, partnership announcements, and financial disclosures. Track progress across key areas: Phase II/III oncology studies, FDA communications, and strategic collaborations enhancing their nanoparticle-based therapies.
Our repository ensures you stay informed about critical developments in HPV-associated cancer treatments, combination therapy research, and infectious disease vaccine progress. Bookmark this page for direct access to PDSB's verified updates, eliminating the need to scour multiple sources.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced its participation in Noble Capital Markets' C-Suite Interview Series, where leadership discussed the company's pipeline and proprietary Versamune® technology. Key topics included the ongoing phase 2 trials of PDS0101 and the anticipated interim data readout from a National Cancer Institute-led trial at ASCO in June. The interview is available on Channelchek and PDS Biotech's website. PDS0101 is being evaluated in partnership with Merck for HPV-associated cancers.
PDS Biotechnology Corporation (PDSB) announced that efficacy and safety data from the NCI's Phase 2 study of PDS0101 for advanced HPV-associated cancers has been accepted for oral presentation at the ASCO 2021 Annual Meeting, scheduled for June 4-8. The trial demonstrated preliminary efficacy with a response from 3 of the first 8 patients, leading to expanded enrollment. The study focuses on a combination of PDS0101, M9241, and bintrafusp alfa. Dr. Lauren V. Wood expressed optimism regarding the study's potential in immunotherapy.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced the release of its financial results for Q1 2021 on May 13, 2021, prior to market open. Following this release, management will conduct a conference call at 8:00 am ET to discuss the results and provide a business update. The call will also be available as a live webcast, and an archived version will be accessible on the company’s website for six months. PDS Biotech focuses on developing cancer therapies and vaccines using its proprietary Versamune® T-cell activating technology.
PDS Biotechnology Corporation (Nasdaq: PDSB) will participate in Noble Capital Markets’ Virtual Road Show on April 21, 2021, at 1 PM EDT. The event includes a corporate presentation by CEO Dr. Frank Bedu-Addo, CMO Dr. Lauren Wood, and CFO Seth Van Voorhees, followed by a Q&A session. Registration is free for all investors. PDS Biotech focuses on developing cancer therapies and infectious disease vaccines using its proprietary Versamune® technology, which activates T-cells and enhances immune responses. For more information, visit their website.
PDS Biotechnology Corporation (Nasdaq: PDSB) reported its financial results for the year ending December 31, 2020, revealing a net loss of $14.8 million ($0.89 per share), a rise from a $7.0 million loss in 2019. R&D expenses increased to $7.9 million, while G&A expenses decreased to $7.0 million. Key developments include the initiation of Phase 2 trials for PDS0101 in combination with KEYTRUDA® and chemoradiotherapy. Additionally, PDSB received a $60 million commitment from Brazil’s Ministry of Science, Technology and Innovation for the development of its COVID-19 vaccine PDS0203.
PDS Biotech, along with Farmacore Biotechnology and Blanver Farmoquímica, announced a commitment of approximately US$60 million from Brazil's MCTI for the development of a second-generation COVID-19 vaccine utilizing the Versamune® technology. The funding will support a combined Phase 1/2 clinical trial expected to begin in Q2/3 2021, pending approval by Anvisa. The trial aims to enroll around 360 patients, focusing on the vaccine's safety and efficacy. The consortium plans to scale up manufacturing in anticipation of positive trial results.
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy firm, will announce its financial results for the year ended December 31, 2020, on March 18, 2021, before market opening. The announcement will be followed by a conference call at 8:00 am ET to discuss the results and provide a business update. PDS Biotech focuses on innovative cancer therapies and vaccines using its proprietary Versamune® technology, designed to activate immune responses effectively.
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company, announced that CEO Frank Bedu-Addo will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10 and the 31st Annual Oppenheimer Healthcare Conference on March 16. Both events will be hosted virtually, with presentations available on-demand and live. Replays will be accessible on the company’s investor relations website for 90 days post-conference. PDSB develops innovative cancer therapies and vaccines utilizing their proprietary Versamune® technology.
PDS Biotechnology Corporation (PDSB) has announced a partnership with Blanver Farmoquímica e Farmacêutica S.A. and Farmacore Biotechnology to develop and commercialize a COVID-19 vaccine in Latin America. Blanver will handle the manufacturing and distribution of this Versamune®-based vaccine, while Farmacore will lead regulatory and clinical trial efforts in Brazil. The vaccine, which showed significant T-cell activation in preclinical studies, represents a promising approach to combat COVID-19 without using live viruses or traditional adjuvants. Clinical trials are expected to begin in the first half of 2021.
PDS Biotechnology (Nasdaq: PDSB) announced progress in its Phase 2 clinical study of PDS0101 for advanced HPV-associated cancers. Full enrollment was triggered by observing 3 objective responses in the initial cohort of 8 patients. The trial, led by the National Cancer Institute, evaluates PDS0101 in combination with the immune-modulating agents bintrafusp alfa and NHS-IL12. The study aims to assess efficacy in both checkpoint inhibitor-naïve and refractory patients. The company's proprietary Versamune® technology aims to enhance immune response against cancer.
